title: Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study.
abstract: OBJECTIVE
  The use of atypical antipsychotics (AAPs) for the treatment of unipolar and bipolar depression has been more and more frequently evaluated, and aripiprazole showed positive effects in the treatment of unipolar depression. However, no placebo-controlled studies of adjunctive aripiprazole for the treatment of bipolar depression have been performed yet.
  
  
  METHODS
  In this prospective, double-blind, placebo-controlled, randomized trial, 23 inpatients with bipolar depression according to DSM-IV criteria were included. Before randomization, patients had to be on a constant mood stabilizer treatment with lithium or valproate for at least 1 week. After inclusion, all patients were openly treated with additional citalopram and with additional aripiprazole or placebo for 6 weeks. The primary outcome parameter was the reduction in depressive symptoms according to the Hamilton Depression Rating Scale (HDRS) within 6 weeks.
  
  
  RESULTS
  After 6 weeks of treatment, the HDRS score decreased in both groups. There was no significant difference between both the groups at any point of time with respect to the HDRS.
  
  
  CONCLUSIONS
  Derived from this small pilot study, adjunctive aripiprazole does not seem to be a promising strategy for the acute treatment of bipolar depression. However, this lack of additional benefit seems to stem from the already good effectiveness of the control group, namely the treatment with citalopram.
authors.affiliation: Department of Psychiatry and Psychotherapy, Charité-University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany. arnim.quante@charite.de
authors.forename: Arnim
authors.initials: A
authors.lastname: Quante
authors.forename: Sara
authors.initials: S
authors.lastname: Zeugmann
authors.forename: Alexander
authors.initials: A
authors.lastname: Luborzewski
authors.forename: Nicole
authors.initials: N
authors.lastname: Schommer
authors.forename: Jens
authors.initials: J
authors.lastname: Langosch
authors.forename: Christoph
authors.initials: C
authors.lastname: Born
authors.forename: Ion
authors.initials: I
authors.lastname: Anghelescu
authors.forename: Juergen
authors.initials: J
authors.lastname: Wolf
mesh_terms: D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D001714:Bipolar Disorder / Q000188:drug therapy*; D015283:Citalopram / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D000068180:Aripiprazole; D015283:Citalopram; D010879:Piperazines; D015363:Quinolones; D017367:Selective Serotonin Reuptake Inhibitors